ZYNE - Zynerba Pharmaceuticals, Inc.
| Previous Close | 10.31 |
| Open | 10.36 |
| Bid | 9.90 x 100 |
| Ask | 10.55 x 100 |
| Day's Range | 10.01 - 10.64 |
| 52 Week Range | 5.42 - 24.57 |
| Volume | 199,093 |
| Avg. Volume | 319,691 |
| Market Cap | 143.208M |
| Beta | 4.94 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.48 |
| Earnings Date | Aug 9, 2017 - Aug 14, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 17.81 |
- Investor's Business Daily•3 days ago
Can Cannabis Treat Seizures? Biotechs Say The Answer Is Yes
GW Pharmaceuticals, Insys Therapeutics and Zynerba Pharmaceuticals are using cannabis-based therapies to treat a myriad of disorders, including seizures.
- GlobeNewswire•4 days ago
Zynerba Pharmaceuticals Appoints John P. Butler to Board of Directors
DEVON, Pa., April 16, 2018-- Zynerba Pharmaceuticals, Inc., a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced ...
- GlobeNewswire•10 days ago
Zynerba Pharmaceuticals Initiates Open-Label Phase 2 Trial of ZYN002 in Developmental and Epileptic Encephalopathies (DEE)
DEVON, Pa., April 10, 2018-- Zynerba Pharmaceuticals, Inc., a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced ...
- Simply Wall St.•17 days ago
Should You Buy Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) At $7.98?
Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE), a pharmaceuticals company based in United States, received a lot of attention from a substantial price movement on the NasdaqGM in the over the last fewRead More...
- GlobeNewswire•25 days ago
Zynerba Pharmaceuticals Announces Publication of Preclinical Data in Neuropsychopharmacology Demonstrating Effect of Cannabidiol Gel Treatment in Reduction of Relapse in an Addiction Model
DEVON, Pa., March 26, 2018-- Zynerba Pharmaceuticals, Inc., a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced ...
- GlobeNewswire•29 days ago
Zynerba Pharmaceuticals Announces Poster Presentation at the 2018 Annual Meeting of the American Academy of Neurology (AAN)
DEVON, Pa., March 22, 2018-- Zynerba Pharmaceuticals, Inc., a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced ...
- Simply Wall St.•last month
Analysts Expect Breakeven For Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE)
Zynerba Pharmaceuticals Inc’s (NASDAQ:ZYNE): Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The US$136.43M market-cap company announced a latest loss of -US$32.01M on 31 December 2017 forRead More...
- GlobeNewswire•last month
Zynerba Pharmaceuticals to Present at the Oppenheimer 28th Annual Healthcare Conference
DEVON, Pa., March 14, 2018-- Zynerba Pharmaceuticals, Inc., a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced ...
- ACCESSWIRE•last month
Today’s Research Reports on Trending Tickers: Kura Oncology and Zynerba Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / March 13, 2018 / U.S. markets were mixed Mondays as concerns over a potential trade war overshadowed Friday’s jobs data. The Dow Jones Industrial Average declined 0.62 percent ...
- Associated Press•last month
Zynerba reports 4Q loss
The Devon, Pennsylvania-based company said it had a loss of 60 cents per share. The results exceeded Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...
- GlobeNewswire•last month
Zynerba Pharmaceuticals Reports Fourth Quarter and Year End 2017 Financial Results and Operational Highlights
DEVON, Pa., March 12, 2018--. Zynerba Pharmaceuticals, Inc., a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced ...
- ACCESSWIRE•last month
Wired News – Zynerba Pharma Held Positive Discussion Meeting with FDA for its ZYN002 Development Strategy
Stock Monitor: Horizon Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 07, 2018 / Active-Investors.com has just released a free research report on Zynerba Pharma, Inc. (NASDAQ: ZYNE ). If ...
- American City Business Journals•2 months ago
Main Line pharma company plans key study of Fragile X syndrome therapy
Zynerba Pharmaceuticals said Monday it plans — with the Food and Drug Administration's approval — to initiate a single pivotal study later this year to support a new drug application for its experimental cannabis-based treatment for Fragile X Syndrome. Fragile X is a rare genetic developmental disability that is a leading known cause of both inherited intellectual disability and autism spectrum disorder. Zynerba, of Devon, Pa, said its game plan for its new drug candidate, ZYN002, came following a meeting with the Food and Drug Administration.
- GlobeNewswire•2 months ago
Zynerba Pharmaceuticals Announces Positive Meeting with U.S. Food and Drug Administration and Plans to Conduct a Single Pivotal Study of ZYN002 in Fragile X Syndrome to Support an NDA Filing
DEVON, Pa., March 05, 2018-- Zynerba Pharmaceuticals, Inc., a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced ...
- 24/7 Wall St.•3 months ago
Can Zynerba Pharma Shares Really Still Double in These High Times?
While Zynerba's share price is still roughly half of last year's peak, the company has gotten attention from Wall Street with big upside in analyst calls in recent days.
- Motley Fool•4 months ago
Can This Beaten-Down Marijuana Stock Roar Back in 2018?
Zynerba faces some big questions heading into the new year.
- Simply Wall St.•4 months ago
Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE): Does -3.8% EPS Drop In A Year Reflect The Long-Term Trend?
For investors, increase in profitability and industry-beating performance can be essential considerations in an investment. Below, I will examine Zynerba Pharmaceuticals Inc’s (NASDAQ:ZYNE) track record on a high level, toRead More...
- ACCESSWIRE•4 months ago
Today’s Research Reports on Trending Tickers: Achillion Pharmaceuticals and Zynerba Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / December 5, 2017 / U.S. markets saw mixed Monday as the Dow reached a new record after investors celebrated the passing of a bill to overhaul the country's tax system while ...
- Benzinga•5 months ago
Zynerba Pharmaceuticals Volatile After Epilepsy Study Results
Shares of Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE ), a specialty pharmaceutical company that focuses on developing and commercializing pharmaceutically produced transdermal cannabinoid treatments, traded ...
- Simply Wall St.•5 months ago
Is It The Right Time To Buy Zynerba Pharmaceuticals Inc (ZYNE)?
Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE), a pharmaceuticals company based in United States, received a lot of attention from a substantial price increase on the NasdaqGM in the over the last fewRead More...
- Associated Press•5 months ago
Zynerba reports 3Q loss
On a per-share basis, the Devon, Pennsylvania-based company said it had a loss of 63 cents. The results fell short of Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...
